Natural History Study of Patients With Neurofibromatosis Type I
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1
Sponsor: National Cancer Institute (NCI)
A observational or N/A phase clinical study on Malignant Peripheral Nerve Sheath Tumor and Neurofibroma, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 67 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)Background Neurofibromatosis Type 1 (NF1) is an autosomal dominant, progressive genetic disorder characterized by diverse clinical manifestations. Patients with NF1 have an increased risk of developing tumors of the central and peripheral nervous system including plexiform neurofibromas (PN), dermal neurofibromas, optic pathway tumors, brain tumors, malignant peripheral nerve sheath tumors (MPNST), juvenile myelomonocytic leukemia, and pheochromocytomas. In addition, NF1 manifests in essentially every organ system, with for example, skeletal and vascular abnormalities, and cognitive deficits. Thus, the care for individuals with NF1 requires a multidisciplinary approach. The natural history of NF1 related tumor and other manifestations is poorly understood, and for most NF1 related tumor manifestations the only standard treatment option is surgery. The NIH Clinical Center provides the ideal infrastructure for evaluation of the natural history of rare diseases. A better understanding of the natural history of NF1 related tumor and other manifestations will be helpful for the design of treatment studies. The NCI, POB has an active clinical trials program for NF1 related tumor manifestations including PN, MPNST. Unlike individuals with refractory solid cancers, individuals with NF1 have near normal life expectancy, and their benign tumors progress more slowly than solid cancers. Individuals with NF1 may thus participate...
Background
Neurofibromatosis Type 1 (NF1) is an autosomal dominant, progressive genetic disorder characterized by diverse clinical manifestations. Patients with NF1 have an increased risk of developing tumors of the central and peripheral nervous system including plexiform neurofibromas (PN), dermal neurofibromas, optic pathway tumors, brain tumors, malignant peripheral nerve sheath tumors (MPNST), juvenile myelomonocytic leukemia, and pheochromocytomas. In addition, NF1 manifests in essentially every organ system, with for example, skeletal and vascular abnormalities, and cognitive deficits. Thus, the care for individuals with NF1 requires a multidisciplinary approach. The natural history of NF1 related tumor and other manifestations is poorly understood, and for most NF1 related tumor manifestations the only standard treatment option is surgery. The NIH Clinical Center provides the ideal infrastructure for evaluation of the natural history of rare diseases. A better understanding of the natural history of NF1 related tumor and other manifestations will be helpful for the design of treatment studies. The NCI, POB has an active clinical trials program for NF1 related tumor manifestations including PN, MPNST. Unlike individuals with refractory solid cancers, individuals with NF1 have near normal life expectancy, and their benign tumors progress more slowly than solid cancers. Individuals with NF1 may thus participate in multiple treatment trials.
Objectives
The overall purpose of this descriptive NF1 Natural History study is to serve as an umbrella protocol for the ongoing NF1 clinical trials program to allow the longitudinal evaluation of individuals with NF1 for NF1 related tumor and non tumor manifestations irrespective whether they are currently enrolled on a treatment study or not, and to develop a better understanding of the biology of NF1 related manifestations. Following these patients longitudinally will allow investigators to develop a better understanding of the natural history of these manifestations, provide the basis for the development of endpoints for clinical trials and to potentially develop more effective treatments. NF1 manifestations, which will be followed longitudinally, include PN, MPNST, optic pathway tumors, dermal neurofibromas, NF1 associated pain, and neuropsychological, motor, and endocrine function. Patient samples will be collected to investigate the existence of a peripherally detectable disease progression biomarker. A comprehensive treatment plan and recommendations will be developed and communicated with the patient and primary caregivers.
Eligibility
Children, adolescents, and adults with a confirmed clinical diagnosis of NF1 or a confirmed NF1 mutation.
Design
Attempts will be made to have all individuals undergo a comprehensive baseline evaluation including clinical phenotyping, genotyping, imaging of tumor manifestations, and pain, quality of life, neuropsychological, motor, and endocrine evaluations. The NF1 manifestations will be longitudinally monitored with a frequency of every year to every three years, with the extent and timing of follow-up evaluations depending on the findings at baseline.
Status Flow
Change History
67 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
-
Mar 2026 — May 2026 [monthly]
Active Not Recruiting
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting
▶ Show 62 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting
-
Aug 2023 — Oct 2023 [monthly]
Active Not Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting
-
Apr 2023 — Jul 2023 [monthly]
Active Not Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting
-
Jan 2023 — Mar 2023 [monthly]
Active Not Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting
-
Jan 2022 — Apr 2022 [monthly]
Active Not Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
Aug 2020 — Nov 2020 [monthly]
Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Recruiting
-
May 2020 — Jun 2020 [monthly]
Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting
-
Jun 2019 — Nov 2019 [monthly]
Recruiting
-
May 2019 — Jun 2019 [monthly]
Recruiting
-
Apr 2019 — May 2019 [monthly]
Recruiting
-
Jan 2019 — Apr 2019 [monthly]
Recruiting
-
Oct 2018 — Jan 2019 [monthly]
Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
Recruiting NA
-
May 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
Background: Neurofibromatosis Type 1 (NF1) is a genetic disorder in which patients are at increased risk of developing tumors (usually non-cancerous) of the central and peripheral nervous system. The disease affects essentially every organ system. The natural course of NFI over time is poorly understood. For most patients the only treatment option is surgery. A better understanding of NF1 may be helpful for the design of future treatment studies. Objectives: To evaluate people with NF1 over 10 years in order to better understand the natural history of the disease. To characterize the patient population and to examine how NFI affects patients quality of life and function. Eligibility: Children, adolescents, and adults with NF1. Design: Participants have a comprehensive baseline evaluation including genetic testing, tumor imaging, pain and quality-of-life assessments, and neuropsychological, motor and endocrine evaluations. Patients are monitored every 6 months to every 3 years, depending on their individual findings at the baseline study. Tests may include the following, as appropriate: * Medical history, physical examination and blood tests. * Whole body and face photography to monitor visible deformities. * Neuropsychological testing, quality-of-life evaluations, motor function tests, endocrinologic evaluations, heart and lung function tests, hearing tests, bone density scans and other bone evaluations. * MRI and PET scans to detect and assess plexiform neurofibromas (tumors that arise from nerves and can cause serious problems), paraspinal neurofibromas (tumors that arise from nerves around the spine and can cause problems by compressing the spinal cord), and malignant peripheral nerve sheath tumors (a type of cancer that arises from a peripheral nerve or involves the sheath covering the nerve). * Eye exams, MRI scans and PET scans to evaluate optic pathway gliomas (tumors arising from the vision nerves or the brain areas for vision) and the chemicals within the tumor and brain. * Eye exams and photographs to evaluate the development of Lisch nodules (non-cancerous tumors on the eye). * Photographs of dermal neurofibromas (tumors of the skin), cafe-au-lait spots (dark or pigmented areas on the skin that are often the first signs of NF1) and other skin problems. * Pain evaluations to monitor the different types of pain patients experience, causes of the pain, how often the pain occurs, effect of the pain on quality of life, and what pain medications and alternative treatments, such as acupuncture, are effective.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .